Yahoo Poland Wyszukiwanie w Internecie

Search results

1. www.idsociety.org › practice-guideline › amr-guidanceIDSA 2024 Guidance on the Treatment of Antimicrobial Resistant...

   www.idsociety.org › practice-guideline › amr-guidance

   • Zapisane w pamięci cache

   12 lip 2024 · This guidance document provides recommendations to clinicians for treatment of infections caused by extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and difficult-to-treat Pseudomonas aeruginosa (DTR-P. aeruginosa).

   • Infection Prevention & Control

     IDSA/SHEA: Primer on Healthcare Epidemiology, Infection...

   • Guideline Development Process

     Because of the large number of clinical practice guidelines...

   • Ebola

     What is Ebola? Ebola virus disease is a severe illness that...

   • Evaluation and Management Services

     Dr. Timothy Sullivan, Vice Chair of IDSA’s Coding & Payment...

   • Bio-Preparedness Workforce Pilot

     On Thursday, June 15, in Washington, D.C., Axios health care...

   • Lyme Disease

     IDSA engages in advocacy efforts that support better Lyme...

   • ID Match

     The IDSA ID Match Resolution provides guiding principles for...

   • Hepatitis C

     Viral hepatitis is a silent epidemic. According to the...

2. academic.oup.com › cid › articleInfectious Diseases Society of America 2022 Guidance on the...

   academic.oup.com › cid › article

   19 kwi 2022 · For this guidance document, ESBL-E will refer to presumed or confirmed ESBL-producing E. coli, K. pneumoniae, K. oxytoca, or P. mirabilis. Treatment recommendations for ESBL-E infections listed below assume that in vitro activity of preferred and alternative antibiotics has been demonstrated.

3. www.nature.com › articles › s41598/024/75791-6Decolonization strategies for ESBL-producing or...

   www.nature.com › articles › s41598/024/75791-6

   17 paź 2024 · Decolonization is an effective measure to prevent colonized patients from progressing to ESBL-E/CRE infection and can control the spread of ESBL-E/CRE in the population at source.

4. www.ecdc.europa.eu › en › publications-dataSystematic review of the effectiveness of infection control...

   www.ecdc.europa.eu › en › publications-data

   • Zapisane w pamięci cache

   8 gru 2014 · This systematic review seeks to identify evidence for the effectiveness of targeted infection control measures to control the spread and transmission of ESBL-E when transferring patients between healthcare settings, especially when the transfer is cross-border.

5. www.ncbi.nlm.nih.gov › pmc › articlesTrends in prevalence of extended-spectrum...

   www.ncbi.nlm.nih.gov › pmc › articles

   11 sie 2021 · The microbiology laboratory reports extended-spectrum beta-lactamase producing E. coli (ESBL-E. coli) as an E. coli strain resistant to ceftazidime or cefotaxime and inhibited by clavulanic acid using broth microdilution, per 2016 CLSI guidelines . Results reported as “intermediate resistance” were considered resistant in this study ...

6. academic.oup.com › cid › articleInfectious Diseases Society of America Guidance on the Treatment...

   academic.oup.com › cid › article

   • Zapisane w pamięci cache

   27 paź 2020 · This guidance document provides recommendations for the treatment of infections caused by extended-spectrum β-lactamase–producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa).

7. www.gov.uk › government › publicationsExtended-spectrum beta-lactamases (ESBLs): FAQs - GOV.UK

   www.gov.uk › government › publications

   • Zapisane w pamięci cache

   1 gru 2013 · ESBL-producing strains are bacteria that produce an enzyme called an extended-spectrum beta-lactamase, which makes them more resistant to antibiotics and makes the infections harder to treat....